Investor Relations

Corporate Profile

Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).

Change

Volume

52 Week High

52 Week Low

Apr 15, 2021 8:36 PM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 12, 2021

FOSTER CITY, Calif. --(BUSINESS WIRE)--Apr. 12, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on April 12, 2021 , the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 118,800 shares of common stock to

Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis

April 12, 2021

- Mirum expands potential opportunities across rare disease pipeline - Vivet to lead pre-clinical development of its two gene therapy programs for PFIC3 and PFIC2 - Mirum gains option to license VTX-803 and VTX-802 FOSTER CITY, Calif. & PARIS--(BUSINESS WIRE)--Apr.

Mirum Pharmaceuticals Announces FDA Acceptance of New Drug Application and Priority Review for Maralixibat in Alagille Syndrome

March 29, 2021

- PDUFA action date is September 29, 2021 . - Priority review and Rare Pediatric Disease Designation granted. - FDA has indicated that advisory committee is not currently planned. FOSTER CITY, Calif. --(BUSINESS WIRE)--Mar. 29, 2021-- Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 10, 2021

FOSTER CITY, Calif. --(BUSINESS WIRE)--Mar. 10, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on March 10, 2021 , the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 114,800 shares of common stock to

Events

Oppenheimer 31st Annual Healthcare Conference

Mar 17, 2021 at 3:50 PM EDT

H.C. Wainwright Global Life Sciences Conference

Mar 9, 2021

Raymond James Virtual Institutional Investors Conference

Mar 3, 2021 at 3:00 PM EST

Click here for webcast

Investor Relations

Investor Relations

Corporate Profile

Header Menu